Key facts
- It has raised $8.0M; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include Tampa Bay Wave, Capita3, Divergent Capital (New York), Freya Ventures, MedTech Accelerator — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Paterna BioSciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Paterna BioSciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Paterna BioSciences
Operator of a biotechnology company intended to develop an in vitro spermatogenesis process to improve human reproductive health. The company uses a patented process to isolate testicular spermatogonial stem cells and uses ligands and iterative chaperoned machine learning to guide spermatogenesis for intracytoplasmic sperm injection, enabling healthcare professionals to solve male infertility and improve offspring health.
- Sector
- Healthcare
- HQ
- Salt Lake City, UT, United States
- Founded
- 2020
- Employees
- 22
- Website
- paternabio.com/
- Ownership
- Privately Held (backing)
Paterna BioSciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Paterna BioSciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Paterna BioSciences in its N-PORT filings yet. We sweep new filings monthly.